Multifocal motor neuropathy


Multifocal motor neuropathy (MMN) is an immune-mediated disorder characterised by slowly progressive, asymmetrical weakness of limbs without sensory loss. The clinical presentation of MMN mimics that of lower-motor-neuron disease, but in nerve-conduction studies of patients with MMN motor-conduction block has been found. By contrast with chronic inflammatory demyelinating polyneuropathy, treatment with prednisolone and plasma exchange is generally ineffective in MMN and even associated with clinical worsening in some patients. Of the immunosuppressants, cyclophosphamide has been reported as effective but only anecdotally. Various open trials and four placebo-controlled trials have shown that treatment with high-dose intravenous immunoglobulin leads to improvement of muscle strength in patients with MMN. Although clinical, pathological, imaging, immunological, and electrophysiological studies have improved our understanding of MMN over the past 15 years, further research is needed to elucidate pathogenetic disease mechanisms in the disorder.

In 1985, Parry and Clarke studied nerve conduction in two patients with a lower-motor-neuron syndrome characterised by progressive, asymmetric, predominantly distal weakness without sensory loss and found conduction block. Soon afterwards, others reported patients with similar characteristics. Weakness in patients with a lower-motor-neuron syndrome with conduction block was shown to be reversible with immunomodulating therapy and associated with high titres of IgM antibodies to GM1 ganglioside. Hence, a separate disorder emerged: multifocal motor neuropathy (MMN). The disorder was thought to be immune mediated, possibly through IgM antibodies that bind gangliosides on human peripheral nerves. The differential diagnosis of MMN includes motor-neuron disease and demyelinating neuropathies. Diagnosis of MMN is supported by the finding of motor but not of sensory abnormalities on nerve-conduction studies. Whether conduction block must be present for the diagnosis of MMN is debatable. Various open and placebo-controlled studies have shown that treatment with high-dose intravenous immunoglobulin leads to improvement of muscle strength. Intravenous immunoglobulin is now the first choice in MMN. Many clinical and electrophysiological studies have improved our understanding of MMN in the past 15 years, but the disease mechanisms underlying weakness in MMN are poorly understood.

Clinical features

MMN is characterised by slowly progressive weakness and muscle atrophy that develops gradually over several years. More men than women are affected, at a ratio of 2:6. The mean age at onset is 40 years, with a range of 20–70 years. In almost 80% of patients, the first symptoms occur between age 20 years and 50 years. The most common initial symptoms are wrist drop, grip weakness, and foot drop. Weakness develops asymmetrically and is more prominent in the arms than in the legs. In most patients with onset in the legs, the abnormalities also eventually affect the arms and become the most prominent. Symptoms and signs in the distal muscles prevail for a long time, but eventually weakness in proximal muscle groups of the arms, but not of the legs, may develop. Weakness is typically more pronounced than the degree of atrophy suggests. Nevertheless, atrophy of affected muscles can be substantial in patients with a long disease duration. Other motor symptoms include muscle cramps and fasciculations in about two-thirds of patients. Myokymia has been reported occasionally. Tendon reflexes are commonly reduced in affected regions, although these are rarely brisk in the arms. Single cases of cranial-nerve involvement have been reported. Respiratory failure due to unilateral or bilateral phrenic-nerve palsy can occur, even at the beginning of the disorder. Some patients report feelings of paraesthesia or numbness but sensory loss on objective neurological or neurophysiological assessment should not be found.

Differential diagnosis

The differential diagnosis of MMN includes two different categories of disorders: motor-neuron disease and demyelinating neuropathies. The first signs and symptoms in MMN can be similar to those in motor-neuron disease, and some patients are initially diagnosed as having amyotrophic lateral sclerosis or lower-motor-neuron disease. Slowly progressive disease course, the absence of upper-motor-neuron signs or bulbar signs and the presence of demyelinating features on electrophysiological assessment will eventually differentiate MMN from amyotrophic lateral sclerosis; differentiation of MMN from lower-motor-neuron disease is more difficult. We categorised lower-motor-neuron disease into four types of spinal muscular atrophy: slowly progressive general; distal; segmental distal; and segmental proximal. Clinically, MMN is difficult to differentiate from slowly progressive generalised spinal muscular atrophy or segmental distal spinal muscular atrophy. The finding of persistent motor-nerve conduction block on nerve-conduction studies outside nerve compression sites, a positive titre
of anti-GM1, or high signal intensity on T2-weighted MRI of the brachial plexus can help to differentiate MMN from lower-motor-neuron disease.55

Within the demyelinating neuropathies, the disorders from which MMN must be differentiated are: chronic inflammatory demyelinating polyneuropathy (CIDP), particularly the pure motor form, and the Lewis-Sumner syndrome.56,7,46–51 In patients with CIDP, proximal symmetrical weakness and general areflexia are common, whereas weakness in MMN is asymmetrical and distal, and reflexes are only poor or absent in affected limbs. A remitting and relapsing course or a progression of symptoms in weeks is common in CIDP but not in MMN. The CSF protein concentration in CIDP is normal or slightly increased but rarely higher than 1 g/L, unlike in CIDP, and can therefore help to differentiate between the two.31,23,45 Sensory signs and symptoms also differ for MMN and CIDP. On nerve-conduction studies, motor conduction block is found in both disorders, but other features of demyelination are more prominent in CIDP, such as slowed conduction velocities and prolonged distal latencies.7,14 Another disease entity that has similarities with MMN (and CIDP) is the Lewis-Sumner syndrome (table 1).48–53 Patients with this syndrome have an asymmetrical sensory or sensorimotor demyelinating neuropathy that can be localised to one arm or leg for several years, sometimes associated with neuropathic pain or focal nerve tenderness. Nerve-conduction studies are necessary to diagnose the syndrome and can help to differentiate it from MMN because low action-potential amplitudes in distal sensory nerves are found in many patients with the Lewis-Sumner syndrome, but not in patients with MMN. Patients with the Lewis-Sumner syndrome can benefit from treatment with corticosteroids, whereas those with MMN do not, and can even deteriorate.31,45,16–57

### Diagnosis

**Electrophysiological characteristics**

Conduction block, the failure of a nerve impulse to propagate through a structurally intact axon, is the electrophysiological hallmark of MMN in motor conduction studies (figure 1).1,4,18–23,28,58 Conduction block in a sufficient number of axons can be detected as a lower amplitude or area of the compound muscle action potential (CMAP) on proximal stimulation of a nerve segment than on distal stimulation of that segment (proximal/distal decrement in CMAP; figure 1). As well as conduction block, two other mechanisms can lead to CMAP decrement.31,60 When axons within a nerve have different conduction times (known as temporal dispersion), the positive phase of fast-motor-unit action potentials coincides with the negative phase of slow-motor-unit action potentials, yielding increased duration of the proximal compared with the distal CMAP, phase cancellation, and CMAP decrement. Furthermore, polyphasia of the motor-unit action potentials that contribute to the CMAP (due to collateral sprouting) has been assumed to yield increased phase cancellation and, consequently, a greater CMAP decrement. Because the occurrence of temporal dispersion and polyphasic motor-unit action potentials can yield CMAP decrement and mimic conduction block in peripheral polyneuropathies and lower-motor-neuron disease,41,42 criteria to separate conduction block from the other mechanisms that can cause CMAP decrement are needed. A simulation study in rats, in which compound muscle-unit action potentials were reconstructed from motor-unit action potentials, showed that maximum temporal dispersion could result in a decrement of the CMAP area of up to 50%.39 No simulation studies with human polyphasic motor-unit action potentials and realistic temporal dispersion have been done. Consequently, a decrease in the CMAP area of more than 50% is currently the best indication that conduction is blocked in one or more axons of a nerve. Evidence is lacking for various other criteria for conduction block, which are based on expert opinions that have been established by consensus.51

Whether conduction block is always part of MMN is an important issue and depends on the criteria for conduction block and the number of nerves investigated. We reviewed studies in which patients with lower-motor-neuron syndromes were treated with intravenous immunoglobulin, to assess whether or not conduction block was present (table 2). In nerves with limited temporal dispersion (<30%), a criterion consisting of a CMAP (area or amplitude) decrement of at least 50% was fulfilled in none,42 or in few patients who responded positively to intravenous immunoglobulin.42 This number increased when conduction block criteria allowed more temporal dispersion, required less CMAP decrement, or a combination of both.43,44 The American Academy of Electrodiagnostic Medicine proposed research criteria

<table>
<thead>
<tr>
<th>Distribution</th>
<th>MMN</th>
<th>Lower-motor-neuron disease</th>
<th>CIDP</th>
<th>Lewis-Sumner syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prominent sensory symptoms</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Reflex pattern</td>
<td>Decreased in affected regions</td>
<td>Decreased in affected regions</td>
<td>General areflexia</td>
<td>Decreased in affected regions</td>
</tr>
<tr>
<td>Disease course</td>
<td>Slowly progressive</td>
<td>Slowly progressive</td>
<td>Progressive or relapsing</td>
<td>Progressive or relapsing</td>
</tr>
<tr>
<td>Laboratory features</td>
<td>CSF protein &gt;1 g/L</td>
<td>No</td>
<td>No</td>
<td>Rare</td>
</tr>
<tr>
<td>Anti-GM1 antibodies</td>
<td>30–50% of patients</td>
<td>Yes</td>
<td>10% of patients</td>
<td>Rare</td>
</tr>
<tr>
<td>Abnormal MRI of brachial plexus</td>
<td>Asymmetrical*</td>
<td>No</td>
<td>Symmetrical</td>
<td>Asymmetrical*</td>
</tr>
</tbody>
</table>

*Corresponding with neurological deficit; †deterioration can occur.55

Table 1: Comparison of typical features of MMN, lower-motor-neuron disease, CIDP, and the Lewis-Sumner syndrome.
that specified the degree of temporal dispersion for nerves and for segments within nerves, and they found conduction block in 60–70% of patients with a favourable response to intravenous immunoglobulin.45,68 Criteria less stringent than those proposed by the American Academy of Electrodiagnostic Medicine, requiring a compound-muscle-action-potential area decrement of at least 50% in arm or leg nerves, or a compound-muscle-action-potential amplitude decrement of at least 30% in arm nerves, were fulfilled in all patients with a favourable response to intravenous immunoglobulin when a large number of arm and leg nerves, including those innervating non-weakened muscles, were studied bilaterally.23,45 For this reason we prefer criteria for conduction block that require a CMAP area decrement of at least 50% or a CMAP amplitude decrement of at least 30%. These criteria were not fulfilled in all patients with a favourable response to intravenous immunoglobulin when a small number of arm and leg nerves were studied unilaterally.69 In MMN, conduction block according to these criteria is most likely to be found in long arm nerves that innervate weakened muscles. If conduction block cannot be found in these nerves in patients with a lower-motor-neuron syndrome, electrophysiological assessment should be extended to other nerves, including long, intermediate, or short arm nerves innervating weakened or non-weakened muscles.

---

**Figure 1:** Conduction studies in patients with MMN

Motor conduction (left) and sensory conduction (middle) in the ulnar nerve, recorded from the fifth abductor digit muscle. Definite conduction block (a decrease of more than 50% in the CMAP area) and motor conduction velocity compatible with demyelination were found in the upper arm segment. No abnormalities in sensory conduction were found. Motor conduction in the median nerve of a different patient (right) recorded from the left and middle abductor pollicis brevis muscle. Increased temporal dispersion (a prolongation of more than 30% in the CMAP duration) and probable conduction block (a decrease of more than 30% in the CMAP amplitude) were found in the lower arm segment and probable conduction block was found in the upper arm segment. Elbow d=stimulation 5 cm distally from elbow, elbow p=stimulation 5 cm proximally from elbow.
on both sides, until conduction block is found.22 Because no favourable response to immune-modulating treatment has ever been reported for a patient with a lower-motor-neuron syndrome without conduction block, on extensive nerve-conduction studies we restrict treatment to patients with conduction block.

The detection of conduction block can be further improved by fatigability testing69 or root stimulation,78,79 both of which show conduction block in nerves in which it is not found on conventional nerve-conduction studies in a restricted number of nerves. Motor conduction is typically slow in MMN, as it is in CIDP and sporadically in motor-neuron disease.23,46,72 Sensory-nerve-conduction studies are needed to exclude sensory abnormalities (at the site of conduction block) in MMN and can help to differentiate MMN from CIDP. Low distal CMAP amplitudes on nerve conduction studies, suggestive of axonal degeneration, as well as signs of denervation and re-innervation on needle electromyography, occur in MMN, lower-motor-neuron disease, and CIDP.46,72-75 Because of axonal degeneration in MMN, needle electromyography cannot differentiate between MMN and lower-motor-neuron disease. Nerve-conduction studies in patients with a lower-motor-neuron syndrome are therefore important.

Laboratory characteristics

Results of routine analysis of blood and urine are unremarkable in patients with MMN, despite slightly to moderately high serum creatine-kinase activity, consistent with slowly progressive axonal degeneration, in up to two-thirds of patients.12,13 In MMN, oligoclonal bands are not found in the CSF and the IgG index is normal.19 Immunofixation electrophoresis is typically normal in MMN; if a monoclonal spike is seen, the disease should be differentiated from polynuropathy associated with monoclonal gammopathy of unknown significance. Serum immunoglobulin concentrations are high in some patients, but they are polyclonal.12,13,20,49,45,77 Initial reports of increased antibodies to GM1 ganglioside in patients with a lower-motor-neuron syndrome and conduction block in nerve-conduction studies raised hopes for a diagnostic marker for MMN.4,22,30,39,77-79 Positive findings for polyclonal anti-GM1 in about half of the patients with MMN (range 22–85%), as well as in patients with lower-motor-neuron disease, amyotrophic lateral sclerosis, and CIDP, and even in healthy people, suggested that the sensitivity and specificity of antibody testing are limited.4,27,77,80-85 However, in healthy people and patients with disorders other than MMN, the titres of anti-GM1 are typically much lower than in MMN. Several studies have shown that high titres of IgM anti-GM1 are found in patients with Guillain–Barré syndrome, MMN, or lower-motor-neuron disease.49,46-48 Furthermore, a positive IgM anti-GM1 test was associated with MMN within a group of patients with lower-motor-neuron syndrome.49 Moreover, a meta-analysis on the diagnostic value of IgM anti-GM1 in MMN showed that probabilities before the test between 20% and 60% for having MMN on the basis of clinical characteristics changed to probabilities between 50% and 85% when IgM anti-GM1 was found.49 Overall, these studies show that a positive test in a patient with a lower-motor-neuron syndrome is supportive but not conclusive of a diagnosis of MMN and should prompt extensive electrophysiological assessment, whereas a negative test has no diagnostic value.

Neuromaging

In patients with MMN, signal intensity on T2-weighted images of the brachial plexus was asymmetrical and high, corresponding with the distribution of

---

**Table 2: Presence of conduction block in patients with lower-motor-neuron syndromes who were treated with intravenous immunoglobulin**

| Reference | Number of patients | Standard protocol | Nerves investigated | Bilateral | Conduction block criteria | Number of patients | Positive response to treatment with intravenous immunoglobulin/total treated |
|-----------|--------------------|-------------------|-------------------|-----------|---------------------------|--------------------|--------------------------------|--------------------------------|
| 20        | 16                 | Med, Ulr, Per, Tib| Unknown           |           | Amplitude and area >50%   | <30%               | 5                              | 2/3                           |
|           |                    |                   |                   |           |                           | >30%               | 6                              | 4/4                           |
| 23        | 39                 | Med, Ulr, Rad, Mef, Mux, Per, Tib| Yes |           | Area >50%               |                        | 30                             | 30/30                        |
|           |                    |                   |                   |           |                           | Amplitude >30%     | 9                              | 9/9                           |
| 42        | 10                 | Med, Ulr, Per, Tib| No                |           | Amplitude and area >50%   | <30%               | 0                              | 4/10                          |
| 45        | 37                 | Med, Ulr, Rad, Mef, Mux, Per, Tib| Yes |           | Area >50%               |                        | 21                             | 17/21                        |
|           |                    |                   |                   |           |                           | amplitude >30%     | 12                             | 6/12                          |
| 67        | 5                  | Unknown           | Unknown           |           | Amplitude >50%            | <15%               | 0                              | 3/4                           |
| 68        | 23                 | Med, Ulr, Per, Tib| No                |           | AAEM                      | AAEM               | 14                             | 12/14                        |
|           |                    |                   |                   |           | AAEM-10%                  | AAEM               | 14                             | 12/14                        |
| 69        | 9                  | Med, Ulr, Rad, Mux, Per, Tib| No   |           | Amplitude or area >30%   |                      | 0                              | 3/6                           |

Med = median nerve recorded from abductor pollicis brevis; Ulr = ulnar nerve recorded from fifth abductor digitii; Rad = radial nerve recorded from extensor carpi ulnaris; Mef = median nerve recorded from flexor carpi radialis; Mux = musculocutaneus nerve recorded from biceps brachii; Per = deep peroneal nerve recorded from extensor digitorum brevis; Tib = tibial nerve recorded from abductor hallucis. AAEM = criteria proposed by the American Academy of Electrodiagnostic Medicine; AAEM-10% = criteria that require 10% less decrement in amplitude on proximal versus distal stimulation or area for conduction block than those proposed by the AAEM. Patients with a positive response to intravenous immunoglobulin were selected; 33 patients were previously reported in a study by Van den Berg-Vos 2001.45 Patients with a conduction block or other features of demyelination on nerve-conduction studies were selected; 8 patients were selected on the absence of conduction block.
Furthermore, Kaji and colleagues showed large-diameter thin myelinated axons in relation to axon diameter. The findings in MMN resemble the symmetrical high signal intensity seen in CIDP and might be due to demyelination. MRI might help to differentiate MMN from lower-motor-neuron disease; although MRI is normal in the latter, signal intensity is high in about 40–50% of patients with MMN.

Diagnostic criteria
Most diagnostic studies of MMN have focused on the diagnostic yield of criteria for conduction block, whereas there are few data on the additional diagnostic value of clinical and laboratory characteristics. We found that not only the presence of conduction block, but also the age at onset, number of affected limb regions, high signal intensity on T2-weighted images of the brachial plexus, and high titres of anti-GM1 predicted a positive response to intravenous immunoglobulin treatment in patients with lower-motor-neuron syndromes. From these findings, we proposed a set of criteria, consisting of combined clinical, laboratory, and electrophysiological characteristics, for definite, probable, and possible MMN (panel). In a group of patients with lower-motor-neuron syndromes and conduction block or conduction slowing compatible with demyelination on nerve-conduction studies, the likelihood of responding to intravenous immunoglobulin treatment was 81% for definite MMN, 71% for probable MMN, and 11% for possible MMN. Because our criteria improved the identification of patients who might respond favourably to intravenous immunoglobulin, they were proposed for clinical practice but should be validated further.

Pathophysiology
Pathological, immunological, and electrophysiological studies have improved understanding of the typical pattern of weakness (asymmetrical, predominantly distal, more in arm than in leg muscles), the presence of weakness in atrophic and in non-atrophic muscles, the absence of sensory involvement, the partial reversibility of weakness after intravenous immunoglobulin treatment, the poor effect of treatment as the disease progresses, the weakness after intravenous immunoglobulin treatment, and the presence of IgM anti-GM1 in some patients.

Biopsy
Reluctance to take biopsy samples from motor nerves has resulted in few pathological studies in MMN. In an ulnar-nerve biopsy at the site of previously documented conduction block, Auer and colleagues reported onion-bulb formation, which is characteristic of several episodes of demyelination and remyelination, and axons that were thinly myelinated in relation to axon diameter. Furthermore, Kaji and colleagues showed large-diameter axons almost devoid of myelin in the median pectoral nerve with CMAP decrement on intraoperative recording. By contrast, Taylor and colleagues showed that multifocal loss and degeneration of axons, as well as prominent clusters of regenerating axons, dominated over myelin pathology in biopsy samples of motor fascicular nerve with evidence of conduction block on intraoperative

Panel: Proposed diagnostic criteria for MMN
Clinical criteria
1. Slow or stepwise progressive limb weakness
2. Asymmetrical limb weakness
3. Fewer than seven affected limb regions (upper arm, lower arm, upper leg, or lower leg on both sides of body; maximum eight)
4. Tendon reflexes in affected limbs are decreased or absent
5. Signs and symptoms are more pronounced in arms than in legs
6. Age 20–65 years at onset of disease
7. No objective sensory abnormalities except for vibration sense
8. No bulbar signs or symptoms
9. No upper-motor-neuron features
10. No other neuropathies (eg, diabetic, lead, porphyric, or vasculitic neuropathy, CIDP, Lyme neuroborreliosis, post-radiation neuropathy, hereditary neuropathy with liability to pressure palsies, Charcot-Marie-Tooth neuropathies, meningeal carcinomatosis)
11. No myopathy (eg, facioscapulohumeral muscular dystrophy, inclusion-body myositis)

Laboratory criteria
1. CSF protein <1 g/L
2. High anti-GM1 titre
3. High signal intensity on T2-weighted MRI of the brachial plexus

Electrodiagnostic criteria
1. Definite motor conduction block: CMAP area reduction on proximal versus distal stimulation of at least 50% over a long segment (between erb and axilla, upper arm, lower arm, lower leg), or a CMAP amplitude reduction on proximal versus distal stimulation of at least 30% over a short distance (2–5 cm) detected by inching. CMAP amplitude on stimulation of the distal part of the segment with motor conduction block of at least 1 mV
2. Probable motor conduction block: CMAP amplitude reduction on proximal versus distal stimulation of at least 30% over a long segment of an arm nerve. CMAP amplitude on stimulation of the distal part of the segment with motor conduction block of at least 1 mV
3. Slowing of conduction compatible with demyelination: MCV <75% of the lower limit of normal; DML or shortest F wave latency >130% of the upper limit of normal or absence of F waves all after 16–20 stimuli. CMAP amplitude on distal stimulation of at least 0.5 mV

Definite MMN
1–11 on clinical criteria, 1 on laboratory criteria, and 1 and 4 on electrodiagnostic criteria

Probable MMN
1–3 and 6–11 on clinical criteria, 1 on laboratory criteria, and 2 and 4 on electrodiagnostic criteria

Possible MMN
1 and 7–11 on clinical criteria, 2 or 3 on laboratory criteria, and 3 and 4 on electrodiagnostic criteria

CMAP=compound muscle action potential; MCV=motor conduction velocity; DML=distal motor latency; SNAP=sensory nerve action potential.
GM1 antibodies may be pathogenetic in MMN. High GM1 antibody titres suggest that factors other than those blocked by serum samples from patients with or without MMN. The finding that distal motor-nerve conduction in mice was impaired by GM1 antibodies implies that the two disorders are unlikely to share underlying disease mechanisms. The findings in biopsied sural nerves from patients with MMN were either normal or showed mild axonal degeneration, mild demyelination, or both, which is consistent with the infrequent sensory impairment in patients with MMN. Overall, these findings suggest that axonal pathology is more prominent than demyelinating pathology in MMN, they do not explain the finding of conduction block on nerve-conduction studies and the rapid response to intravenous immunoglobulin in patients with MMN. The finding that, unlike CIDP, inflammatory cellular infiltrates are sporadic in MMN implies that the two disorders are unlikely to share underlying disease mechanisms. The findings in biopsied sural nerves from patients with MMN were either normal or showed mild axonal degeneration, mild demyelination, or both, which is consistent with the infrequent sensory impairment in patients with MMN.

**Immunopathology**

The positive response to immunomodulating treatment, the finding of anti-GM1 in 20–80% of patients with MMN, and the expression of GM1 on axon and myelin membranes suggest that anti-GM1 are pathogenetic in MMN. In this context, differences in the fatty-acid and long-chain-base composition of peripheral-nerve ganglioside GM1 between sensory and motor nerves, resulting in different affinities of anti-GM1, could contribute to selective involvement of motor fibres. Antibody-mediated demyelination or blocking of the voltage-gated sodium channels at the node of Ranvier was supported by the results of some invivo and invitro animal experiments, but not in others. Furthermore, anti-GM1 binding sites and voltage gated sodium channels were not colocalised. Moreover, human IgM anti-GM1 modulate intracellular calcium homeostasis in neuroblastoma cells, probably owing to activation of L-type voltage-gated calcium channels that are also present in motor neurons. Overall, these experiments have not confirmed or excluded the pathogeneticity of IgM GM1 antibodies in MMN. The finding that distal motor-nerve conduction in mice was blocked by serum samples from patients with or without high GM1 antibody titres suggests that factors other than GM1 antibodies may be pathogenetic in MMN.

**Electrophysiology**

Conduction block, the electrophysiological hallmark of MMN, was thought to underlie weakness in MMN. Most nerve-conduction studies of patients with MMN found improvement in conduction block after initial and long-term treatment with intravenous immunoglobulin. The inability of nerve-conduction studies to assess proximal nerve segments might explain the lack of improvement in conduction block in some patients. Conduction block might cause weakness that could, at least partly, be reversed by intravenous immunoglobulin. In patients with MMN, long nerves had more segments with conduction block owing to a random distribution of block in arm nerves. Furthermore, distal CMAPs were commonly low in long nerves. Together, these findings suggest length-dependent axonal degeneration due to the high occurrence of conduction block in these nerves.

Electrophysiological studies in patients with MMN who were treated with intravenous immunoglobulin raised important questions about the causes of weakness in MMN. Although muscle strength in patients with MMN improves after intravenous immunoglobulin treatment, it rarely recovers to normal. Irreversible weakness may be caused by irreversible conduction block or axonal degeneration. Many observations suggest that axonal degeneration contributes to weakness in patients with MMN. Atrophic muscles, low distal CMAP amplitudes on nerve-conduction studies, and findings of denervation and re-innervation on needle electromyography are all found in patients with MMN, even in those with a short disease duration. In a study of patients with MMN who had never received intravenous immunoglobulin treatment, a longer disease duration was not only associated with more segments with conduction block, but also with more nerves with low distal CMAP amplitudes, the latter being consistent with progressive axonal degeneration. Weakness due to progressive axonal degeneration was suggested to underlie the less pronounced response to initial (or long-term) intravenous immunoglobulin treatment for patients with a long disease duration. Three long-term follow-up studies of patients on intravenous immunoglobulin maintenance treatment showed a mild decrease in muscle strength as well as continuing axonal degeneration, measured by distal CMAP amplitude. However, in a study that used a high monthly maintenance dose of intravenous immunoglobulin the results were contrasting: weakness was not progressive, and distal CMAP amplitude did not suggest continuing axonal degeneration. To assess the independent contributions of conduction block and axon loss to chronic progressive weakness, we did a multivariate analysis of 20 patients with MMN who were receiving long-term intravenous immunoglobulin treatment. Axon loss, and not conduction block, had the strongest relation to weakness, whereas conduction block alone had the strongest relation to axon loss. These findings suggest that intravenous immunoglobulin treatment affects reversible conduction block but when conduction block is irreversible the affected axons eventually degenerate despite continuous intravenous immunoglobulin treatment. Generally, conduction block occurs when the action current at one node does not induce a sufficiently large depolarisation at the next node to generate an action potential, either because the current available is low or because high current is needed. The finding that...
Conduction block and demyelinating slowing were independently related to each other in the arm nerves of patients with MMN, and the finding of demyelination at the site of conduction block on most biopsy studies, suggests that conduction block results from a primary demyelinating process. In animal experiments, paranodal demyelination impaired saltatory conduction; the current available for depolarisation was low because the outward capacitive sodium current, which leads to depolarisation of the node to be activated, was dissipated over the node and the adjacent damaged paranodal region. The period to depolarise the node to threshold for an action potential will be longer when moderate amounts of current are lost, yielding conduction slowing. With severe loss of current, there will be insufficient current to attain the threshold for an action potential, yielding conduction block. The loss of current may be aggravated when demyelination exposes paranodal or internodal potassium channels. Motor axons in arm nerves have a more prominent slow potassium conductance than motor axons in leg nerves. These differences in conductances could contribute to the greater tendency of motor axons in arm nerves to develop conduction block.

The mechanism that underlies axon loss in MMN is poorly understood. A common disease mechanism that leads to conduction block in some axons and degeneration of other axons could explain the independent relation between axon loss and conduction block. A common disease mechanism is supported by pathological studies showing that the antibodies to the ganglioside GM1 bind to epitopes of the nodal axolemma and paranodal myelin, possibly leading to conduction block and axon loss, and to epitopes of spinal-cord motor neurons, possibly leading to axon loss. Alternatively, the association between axon loss and conduction block might suggest that an axon will eventually degenerate if a process resulting in conduction block affects it. This mechanism is supported by excitability measurements that showed axonal hyperpolarisation adjacent to sites with conduction block. Hyperpolarisation was thought to be secondary to intra-axonal sodium accumulation at the site with conduction block, caused by low activity of the sodium/potassium pump. An animal study of inflammatory demyelination showed that sodium accumulation leads to intra-axonal calcium accumulation due to passive reversal of the sodium/calcium exchanger. An animal study of inflammatory demyelination supported this mechanism, showing that blockade of sodium channels or sodium/calcium exchanger prevented axonal degeneration.

**Treatment**

The hypothesis that MMN is an immune-mediated neuropathy has led to trials of several immunological treatments. By contrast with CIDP, prednisolone and plasma exchange were ineffective in most patients and were even associated with clinical worsening in some patients with MMN. Of the immunosuppressants, only high-dose cyclophosphamide seems to be effective. Unfortunately, the substantial side-effects of cyclophosphamide, especially the risk of neoplasia, restrict its use in patients with MMN.

Many open studies have shown that intravenous immunoglobulin has a beneficial effect. The treatment was effective within a week, but because the effect lasted only a few weeks, maintenance treatment was needed to maintain the effect on muscle strength in most patients. Side-effects were minor; the most disabling were skin changes (eczema) on the hands and trunk. Maintenance of intravenous immunoglobulin treatment is expensive, and many patients find the frequent infusions onerous, but no alternative treatment is available. Therefore, long-term studies are important. We assessed the effects over 4–8 years in 11 patients with MMN. Muscle strength improved substantially within 3 weeks of the start of treatment, and at the last follow-up assessment muscle strength was better than before treatment, even though it decreased slightly during the follow-up period (figure 2). The treatment did not induce remission in any of our patients; when it was stopped, weakness progressed substantially. A study of ten patients on maintenance treatment with intravenous immunoglobulin over 5–12 years showed that the effectiveness tended to decrease when treatment was continued over a long period, even when the dose was increased. During the first few years of maintenance treatment, the response could be restored by increasing the dose, whereas later an increase in dose was only partially effective. However, in another study, a high monthly maintenance dose of immunoglobulin was shown to improve muscle strength and functional disability during long-term follow-up. Study of the efficacy of various long-term doses with a double-blind design is needed.

**Natural course**

Because most patients with MMN respond to intravenous immunoglobulin treatment, a prospective study on the natural course of MMN without any treatment is not feasible. Two retrospective studies on the natural course of MMN have been published; both reported a slowly progressive course. Step-wise and spontaneously remitting disease courses have also been described but are less common than the slow progressive course. In a study of 38 patients with MMN, we showed that disease duration and disease severity are related. Patients who responded to initial intravenous immunoglobulin treatment had a disease duration of up to 24 years and could have severe weakness. Lack of
response to intravenous immunoglobulin was not associated with arm or leg involvement, muscle strength, disability, or electrophysiological variables. Nobile-Orazio and colleagues\(^\text{44}\) showed that the response to initial intravenous immunoglobulin treatment was less pronounced for patients with a longer disease duration. A continuing immunological process might cause progression of weakness in MMN, and early treatment could prevent future progression of weakness and disability in patients with MMN. Although the overall prognosis of patients with MMN seems to be better than that of patients with lower-motor-neuron disease, most patients with MMN have poor dexterity in manual tasks that are a part of daily life.\(^\text{30,42}\) Some patients are disabled by fatigue;\(^\text{39}\) in our opinion this symptom has been underestimated in patients with MMN and needs further study. Death after several years with the disease has been reported in only two patients,\(^\text{35,143}\) whereas in others, death was related to concomitant diseases.\(^\text{38,40}\)

### Conclusion

In the two decades since MMN was first reported, clinical and electrophysiological studies have led to advances in its diagnosis and treatment. The clinical presentation of MMN mimics that of lower-motor-neuron disease, whereas conduction block on motor-conduction studies differentiates between the two. The finding that conduction block presents in patients with MMN suggests that nerve conduction should be extensively studied in every patient with a lower-motor-neuron syndrome until conduction block is found to identify patients who might respond favourably to immunomodulating treatment. In MMN, but not in lower-motor-neuron disease, high doses of intravenous immunoglobulin produce rapid but unsustainable improvement in most patients. Although expensive, repeated intravenous immunoglobulin treatment is effective in maintaining remission and slowing progression of weakness, according to the results of most studies. Despite pathological and immunological studies, the pathogenesis of MMN and the mechanism by which immunoglobulin is effective are poorly understood. Most evidence suggests that conduction block results from a primary demyelinating process and that axonal degeneration in MMN is related to it. Most likely, intravenous immunoglobulin treatment affects reversible conduction block whereas axonal degeneration continues despite intravenous immunoglobulin treatment. Future research on pathogenetic mechanisms is needed so that novel treatment strategies for MMN can be developed.

### Authors’ contributions

J.THHVA, JHHJW, and LVdB planned the review. J.THHVA, RMVdB-V, and LVdB researched relevant research papers. All authors contributed to the writing of the review.

### Conflicts of interest

LVdB has received research grants and honoraria for lecturing from companies that produce intravenous gammaglobulins, including Baxter, Laboratoire Français du fractionnement et des biotechnologies, ZLB Bioplasma Belgium, and Sanguin.

### Role of the funding source

A grant from the Princes Beatrix Fonds supported this review.

### References

318


100 O’Hanlon GM, Paterson GJ, Wilson G, Doyle D, McHardie P, Willison HJ. Anti-GM1 ganglioside antibodies cloned from...


